What we're reading, May 5, 2016: obtaining life-ending medications under California's new law won't be easy come June 9; Arizona is now the only state to not participate in CHIP; struggling insurers propose big premiums increases on Obamacare plans.
When California’s aid-in-dying legislation take effects in June, the process for terminally ill individuals to get medications to end their lives won’t be simple. According to Kaiser Health News, the legislation creates a long list of administrative hurdles for both patients and physicians. The reasons for there being so many steps is to ensure the patient has really thought about the decision and is making it voluntarily.
Arizona has chosen not to restore the federal Children’s Health Insurance Program, making it the only state to not participate in the program. The state’s House voted to restart the program with the caveat that the state can suspend it if fewer federal dollars came in, and the Senate let the bill die due to concerns about the provision, reported The New York Times. The state’s lawmakers initially froze enrollment into the program 6 years ago—30,000 children can enroll in the program, which represents 20% of the uninsured children in Arizona.
As some insurers struggle in the Affordable Care marketplaces, they are proposing big premium increases. The Wall Street Journal reported that the picture will vary state by state as some companies, such as Centene, are profitable, while others, like Humana, expect losses. Humana recently announced it would make changes to its exchange offerings next year, which follows from UnitedHealth Group’s announcement that it would withdraw from most state exchanges in 2017.
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
SGLT2 Inhibitors Show Renal Benefits in HF and CKD as Prescribers Target Uptake Gaps
April 15th 2025Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 inhibitors in heart failure and diabetic kidney disease while emphasizing the need for strategies to increase their uptake in primary care.
Read More
Lifestyle Interventions, Statins, Among Keys to Mitigating CVD Risk in MASLD/MASH
April 15th 2025A recent review highlights the gaps in clinical guidelines and treatment approaches for metabolic dysfunction-associated steatohepatitis (MASH) and looks ahead to the future promise of glucagon-like peptide 1 (GLP-1) receptor agonists for liver conditions.
Read More